Cytokinetics director granted shares and stock options
CYTOKINETICS INC director Robert E. Landry reported equity grants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CYTOKINETICS INC director Robert E. Landry reported equity grants. He received 2,851 shares of Common Stock at no cost, increasing his direct holdings to 10,184 shares. He was also granted a non-qualified stock option for 4,301 shares at an exercise price of $77.15, exercisable starting on June 27, 2026 and expiring on May 26, 2036.
Insider Trade Summary
Grant/Award: 7,152 shares
Grant/Award
2 txns
Insider
Landry Robert E
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (Right to Buy) | 4,301 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 2,851 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 4,301 contracts (Direct);
Common Stock — 10,184 shares (Direct)
Key Figures
Common Stock grant: 2,851 shares
Shares held after grant: 10,184 shares
Option grant size: 4,301 options
+3 more
6 metrics
Common Stock grant
2,851 shares
Award of Common Stock on May 27, 2026
Shares held after grant
10,184 shares
Direct Common Stock holdings following the transaction
Option grant size
4,301 options
Non-qualified stock option for Common Stock
Option exercise price
$77.15 per share
Conversion or exercise price of non-qualified stock option
Option vesting date
June 27, 2026
Exercise date when option first becomes exercisable
Option expiration
May 26, 2036
Expiration date of non-qualified stock option
Key Terms
Non-Qualified Stock Option (Right to Buy), derivative, exercise price, Grant, award, or other acquisition
4 terms
Non-Qualified Stock Option (Right to Buy) financial
"security_title: "Non-Qualified Stock Option (Right to Buy)""
derivative financial
"transaction_type: "derivative" for the stock option grant"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
exercise price financial
"conversion_or_exercise_price: "77.1500" for the option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CYTK director Robert E. Landry report?
Robert E. Landry reported receiving equity awards in Cytokinetics. He was granted 2,851 shares of Common Stock and a non-qualified stock option for 4,301 shares, both recorded as awards rather than open-market purchases or sales.
What are the key terms of Robert E. Landry’s CYTK stock option grant?
Landry received a non-qualified stock option covering 4,301 Cytokinetics shares at an exercise price of $77.15. The option becomes exercisable on June 27, 2026 and expires on May 26, 2036, giving a long-dated right to buy shares at that fixed price.
Was Robert E. Landry’s CYTK Form 4 a market buy or sell?
The Form 4 reports grant or award acquisitions, not market trades. Both the 2,851 Common Stock shares and the 4,301-share option were recorded under code “A” for awards, meaning they were compensation-related, not open-market buying or selling activity.
Does the CYTK Form 4 show any derivative positions for Robert E. Landry?
Yes. The filing shows Landry was granted a derivative security: a non-qualified stock option for 4,301 shares of Common Stock at $77.15. Following this grant, his total reported holdings of this option class are 4,301 derivative securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
